Nicotinamide N-methyltransferase is overexpressed in prostate cancer and correlates with prolonged progression-free and overall survival times

Oncology Letters

Volumn 8, Issue 3, 2014, Pages 1175-1180

  Zhou, Weimin ^a   Gui, Ming ^a   Zhu, Min ^b   Long, Zhi ^a   Huang, Lihua ^a   Zhou, Jun ^a   He, Leye ^a   Zhong, Kuangbiao ^a  

^a THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

^b Central South University   (China)

Author keywords

Immunohistochemistry; Nicotinamide N methyltransferase; Prognosis; Prostate cancer

Indexed keywords

NICOTINAMIDE METHYLTRANSFERASE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MIDDLE AGED; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; TUMOR BIOPSY; VERY ELDERLY;

EID: 84904248752     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2287     Document Type: Article

References (29)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
3. Ross RW, Oh WK, Xie W, et al: Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 26: 842-847, 2008.
4. Debes JD and Tindall DJ: Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351: 1488-1490, 2004.
5. Chen CD, Welsbie DS, Tran C, et al: Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-39, 2004.
6. Choueiri TK, Xie W, D'Amico AV, et al: Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer 115: 981-987, 2009.
7. Bickers B and Aukim-Hastie C: New molecular biomarkers for the prognosis and management of prostate cancer-the post PSA era. Anticancer Res 29: 3289-3298, 2009.
8. Shariat SF, Karam JA and Roehrborn CG: Blood biomarkers for prostate cancer detection and prognosis. Future Oncol 3: 449-461, 2007.
9. Aksoy S, Szumlanski CL and Weinshilboum RM: Human liver nicotinamide N-methyltransferase. cDNA cloning, expression, and biochemical characterization. J Biol Chem 269: 14835-14840, 1994.
10. Rini J, Szumlanski C, Guerciolini R and Weinshilboum RM: Human liver nicotinamide N-methyltransferase: ion-pairing radiochemical assay, biochemical properties and individual variation. Clin Chim Acta 186: 359-374, 1990.
11. Tomida M, Mikami I, Takeuchi S, Nishimura H and Akiyama H: Serum levels of nicotinamide N-methyltransferase in patients with lung cancer. J Cancer Res Clin Oncol 135: 1223-1229, 2009.
12. Roessler M, Rollinger W, Palme S, et al: Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer. Clin Cancer Res 11: 6550-6557, 2005.
13. Sartini D, Pozzi V, Renzi E, et al: Analysis of tissue and salivary nicotinamide N-methyltransferase in oral squamous cell carcinoma: basis for the development of a noninvasive diagnostic test for early-stage disease. Biol Chem 393: 505-511, 2012.
14. Sartini D, Muzzonigro G, Milanese G, et al: Upregulation of tissue and urinary nicotinamide N-methyltransferase in bladder cancer: potential for the development of a urine-based diagnostic test. Cell Biochem Biophys 65: 473-483, 2013.
15. Allred DC, Clark GM, Elledge R, et al: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85: 200-206, 1993.
16. Markert JM, Fuller CM, Gillespie GY, et al: Differential gene expression profiling in human brain tumors. Physiol Genomics 5: 21-33, 2001.
17. Jang JS, Cho HY, Lee YJ, Ha WS and Kim HW: The differential proteome profile of stomach cancer: identification of the biomarker candidates. Oncol Res 14: 491-499, 2004.
18. Xu J, Moatamed F, Caldwell JS, et al: Enhanced expression of nicotinamide N-methyltransferase in human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 88: 4990-4996, 2003.
19. Kim J, Hong SJ, Lim EK, et al: Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis. J Exp Clin Cancer Res 28: 20, 2009.
20. Tang SW, Yang TC, Lin WC, et al: Nicotinamide N-methyltransferase induces cellular invasion through activating matrix metalloproteinase-2 expression in clear cell renal cell carcinoma cells. Carcinogenesis 32: 138-145, 2011.
21. Kim HC, Mofarrahi M, Vassilakopoulos T, et al: Expression and functional significance of nicotinamide N-methyl transferase in skeletal muscles of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 181: 797-805, 2010.
22. Mateuszuk L, Khomich TI, Słomińska E, et al: Activation of nicotinamide N-methyltrasferase and increased formation of 1-methylnicotinamide (MNA) in atherosclerosis. Pharmacol Rep 61: 76-85, 2009.
23. Williams AC and Ramsden DB: Autotoxicity, methylation and a road to the prevention of Parkinson's disease. J Clin Neurosci 12: 6-11, 2005.
24. Sakr WA and Partin AW: Histological markers of risk and the role of high-grade prostatic intraepithelial neoplasia. Urology 57: 115-120, 2001.
25. Emanuelli M, Santarelli A, Sartini D, et al: Nicotinamide N-Methyltransferase upregulation correlates with tumour differentiation in oral squamous cell carcinoma. Histol Histopathol 25: 15-20, 2010.
26. Zhang J: Are poly(ADP-ribosyl)ation by PARP-1 and deacetylation by Sir2 linked? Bioessays 25: 808-814, 2003.
27. Jung-Hynes B, Nihal M, Zhong W and Ahmad N: Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? J Biol Chem 284: 3823-3832, 2009.
28. Parsons RB, Aravindan S, Kadampeswaran A, et al: The expression of nicotinamide N-methyltransferase increases ATP synthesis and protects SH-SY5Y neuroblastoma cells against the toxicity of Complex I inhibitors. Biochem J 436: 145-155, 2011.
29. Ulanovskaya OA, Zuhl AM and Cravatt BF: NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink. Nat Chem Biol 9: 300-306, 2013.